INBX vs. NMRA, ADMA, SANA, RXRX, FUSN, TWST, DNA, BEAM, FDMT, and AUTL
Should you be buying Inhibrx stock or one of its competitors? The main competitors of Inhibrx include Neumora Therapeutics (NMRA), ADMA Biologics (ADMA), Sana Biotechnology (SANA), Recursion Pharmaceuticals (RXRX), Fusion Pharmaceuticals (FUSN), Twist Bioscience (TWST), Ginkgo Bioworks (DNA), Beam Therapeutics (BEAM), 4D Molecular Therapeutics (FDMT), and Autolus Therapeutics (AUTL). These companies are all part of the "biological products, except diagnostic" industry.
Inhibrx (NASDAQ:INBX) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, community ranking, earnings, profitability, valuation, institutional ownership and risk.
82.5% of Inhibrx shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 22.2% of Inhibrx shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Neumora Therapeutics has a net margin of 0.00% compared to Inhibrx's net margin of -13,408.95%. Neumora Therapeutics' return on equity of 0.00% beat Inhibrx's return on equity.
Inhibrx presently has a consensus price target of $27.00, suggesting a potential downside of 21.08%. Neumora Therapeutics has a consensus price target of $22.57, suggesting a potential upside of 140.12%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Neumora Therapeutics is more favorable than Inhibrx.
Inhibrx received 21 more outperform votes than Neumora Therapeutics when rated by MarketBeat users. However, 90.91% of users gave Neumora Therapeutics an outperform vote while only 60.78% of users gave Inhibrx an outperform vote.
Neumora Therapeutics has lower revenue, but higher earnings than Inhibrx.
In the previous week, Neumora Therapeutics had 6 more articles in the media than Inhibrx. MarketBeat recorded 6 mentions for Neumora Therapeutics and 0 mentions for Inhibrx. Neumora Therapeutics' average media sentiment score of 0.12 beat Inhibrx's score of 0.00 indicating that Neumora Therapeutics is being referred to more favorably in the news media.
Summary
Neumora Therapeutics beats Inhibrx on 10 of the 14 factors compared between the two stocks.
Get Inhibrx News Delivered to You Automatically
Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
